Mineral and Bone Disorder in Children with Chronic Kidney Disease Stage I to V (Predialysis)
Author(s) -
Joo Hoon Lee,
Hee Gyung Kang,
Hee Yeon Cho,
Jae Il Shin,
Min Hyun Cho,
Young Seou Park,
Il Soo Ha,
Hae Il Cheong,
Curie Ahn
Publication year - 2014
Publication title -
kidney research and clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.152
H-Index - 20
eISSN - 2211-9140
pISSN - 2211-9132
DOI - 10.1016/j.krcp.2014.05.021
Subject(s) - medicine , kidney disease , hyperphosphatemia , fibroblast growth factor 23 , nephrology , gastroenterology , dialysis , bone mineral , parathyroid hormone , cohort , endocrinology , osteoporosis , calcium
PurposesTo evaluate the mineral and bone disorders in children with chronic kidney disease (CKD) stage I to V predialysis.MethodsPediatric subcohort of KNOW-CKD (KoreaN cohort study for Outcome in patients With CKD) enrolled children (younger than 20 years) with CKD stage I-V (pre-dialysis) from five major pediatric nephrology centers in Korea and collected medical data associated with CKD-mineral and bone disorder.ResultsTotal number of 300 patients (male:female=199:101) was included in this study. Serum phosphorus (mean ± standard deviation 4.89±0.75, 4.6±0.83, 4.63±0.85, 5.13±1.37, 5.35±1.2 from CKD stage I to V, p=0.0002), fibroblast growth factor (FGF)-23 (32.29±42.04, 41.33±41.00, 70.68±121.06, 67.9±66.95, 121.74±139.36, p=0.0030) and the prevalence of hyperphosphatemia (8.51%, 10.64%, 25.53%, 25.53%, 29.79%, p=0.010) increased as CKD progressed. Intact parathyroid hormone (iPTH) increased (40.84±40.37, 44.13±20.2, 78.93±65.21, 181.39±183.86, 313.85±324.95, p<0.001) and serum 1,25D3 level decreased (47.52±21.32, 37.43±12.26, 36.86±25.97, 28.29±15.81, 34.11±21.34, p<0.001) significantly as CKD aggravated. Serum iPTH (r=−0.608, p<0.0001) and FGF-23 (r=−0.4943, p<0.0001) showed negative correlation whereas 1,25D3 (r=0.3288, <0.0001) showed positive correlation with glomerular filtration rate. FGF-23 showed positive correlation with serum phosphorus (r=0.3342, p<0.0001), iPTH (r=0.3214, p<0.0001) and proteinuria (r=0.3609, p<0.0001), and negative correlation with urine phosphorus (r=−0.2597, p=0.0006). The prevalence of patients with increased alkaline phosphatase level increased significantly as CKD progressed (5.66%, 15.09%, 39.62%, 16.98%, 22.64%, p=0.042), which was due to increased prevalence of hyperparathyroidism (p<0.001). Active form vitamin D (0%, 3.77%, 11.88%, 40.74%, 68.89%, p<0.0001), calcium (2.13%, 0%, 9.90%, 4.44%, 62.22%, p<0.0001) and non-calcium phosphorous binders (0%, 0%, 0%, 0%, 13.33%, p<0.0001) were prescribed significantly more often in advanced CKD. Calcium x phosphorus was significantly increased in advanced CKD (11.59%, 17.39%, 28.26%, 21.01%, 21.74%, p=0.002).ConclusionAs CKD progressed, hyperphosphatemia, hyperparathyroidism and 1,25D3 deficiency increased, serum FGF-23 level increased and urinary phosphorus excretion decreased in children with CKD stage I to V predialysis
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom